Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery

2015 ◽  
Vol 34 (5) ◽  
pp. 687-693 ◽  
Author(s):  
Rodrigo A. Ledezma ◽  
Edris Negron ◽  
Gladell P. Paner ◽  
Chris Rjepaj ◽  
Danny Lascano ◽  
...  
Keyword(s):  
Renal Cell ◽  
Survival Outcomes ◽  
Renal Cell Carcinomas ◽  
Similar Survival

scholarly journals Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Jian He ◽  
Kefeng Zhou ◽  
Bin Zhu ◽  
Gutian Zhang ◽  
Xiaogong Li ◽  
...  
Keyword(s):  
Renal Cell ◽  
Gene Fusions ◽  
Renal Cell Carcinomas ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Xp11.2 Translocation ◽  
Clinical Records

Purpose. To compare the differences of CT characteristics between renal cell carcinomas (RCCs) associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 RCCs) and papillary cell renal cell carcinomas (PRCCs). Methods. CT images and clinical records of 64 patients (25 Xp11.2 RCCs, 15 type 1 and 24 type 2 PRCCs) were analyzed and compared retrospectively. Results. Xp11.2 RCC more frequently affected young (30.7±8.7 years) women (16/25, 64%) with gross hematuria (12/25, 48%), while PRCC more frequently involved middle-aged (54.8±11.1 years) men (28/39, 71.8%) asymptomatically. Xp11.2 RCC tended to be heterogeneous density with some showing circular calcification. Lesion sizes of Xp11.2 RCC (5.4±2.2 cm) and type 2 PRCC (5.7±2.5 cm) were significantly larger than that of type 1 PRCC (3.8±1.8 cm). Xp11.2 RCC contained more cystic components (22/25, 88%) than type 1 PRCC (all solid) and type 2 PRCC (9/24, 36.0%). Type 1 PRCC (13/15, 86.7%) and Xp11.2 RCC (21/25, 84.0%) showed more clear boundary than type 2 PRCC (12/24, 50.0%). Conclusion. CT features including diameter, boundary, attenuation, nature, and circular calcification of the tumor, combined with demographic information and symptoms, may be useful to differentiate Xp11.2 RCC from different subtypes of PRCC.

scholarly journals Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses

2004 ◽  
Vol 10 (18) ◽  
pp. 6360S-6366S ◽  
Author(s):  
Patricia Rayman ◽  
Amy K. Wesa ◽  
Amy L. Richmond ◽  
Tanya Das ◽  
Kaushik Biswas ◽  
...  
Keyword(s):  
T Cell ◽  
Renal Cell ◽  
T Cell Responses ◽  
Renal Cell Carcinomas ◽  
Cell Responses

Expression and Amplification of Topoisomerase-2α in Type 1 and Type 2 Papillary Renal Cell Carcinomas and Its Correlation with HER2/neu Amplification

2011 ◽  
Vol 17 (3) ◽  
pp. 697-703 ◽  
Author(s):  
Fusun Duzcan ◽  
Suleyman Ender Duzcan ◽  
Sait Sen ◽  
Kutsal Yorukoglu ◽  
Vildan Caner ◽  
...  
Keyword(s):  
Renal Cell ◽  
Renal Cell Carcinomas

Cytogenetic and morphologic typing of papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors

2004 ◽  
Vol 200 (4) ◽  
pp. 303
Author(s):  
B. Gunawan ◽  
A. Von Heydebreck ◽  
T. Fritsch ◽  
W. Huber ◽  
R.-H. Ringert ◽  
...  
Keyword(s):  
Renal Cell ◽  
Renal Cell Carcinomas ◽  
Cytogenetic Evolution

scholarly journals The Heterogeneity Metabolism of Renal Cell Carcinomas

2021 ◽  
pp. 117-126
Author(s):  
Mohammadreza Zarisfi ◽  
Tu Nguyen ◽  
Jessie R. Nedrow ◽  
Anne Le
Keyword(s):  
Gene Expression ◽  
Renal Cell ◽  
Survival Outcomes ◽  
Metabolic Profiles ◽  
Tumor Type ◽  
Renal Cell Carcinomas ◽  
Cancer Society ◽  
Metabolic Phenotypes ◽  
New Treatments ◽  
Positive Results

AbstractAccording to data from the American Cancer Society, cancer is one of the deadliest health problems globally. Annually, renal cell carcinoma (RCC) causes more than 100,000 deaths worldwide [1–4], posing an urgent need to develop effective treatments to increase patient survival outcomes. New therapies are expected to address a major factor contributing to cancer’s resistance to standard therapies: oncogenic heterogeneity. Gene expression can vary tremendously among different types of cancers, different patients of the same tumor type, and even within individual tumors; various metabolic phenotypes can emerge, making singletherapy approaches insufficient. Novel strategies targeting the diverse metabolism of cancers aim to overcome this obstacle. Though some have yielded positive results, it remains a challenge to uncover all of the distinct metabolic profiles of RCC. In the quest to overcome this obstacle, the metabolic oriented research focusing on these cancers has offered freshly new perspectives, which are expected to contribute heavily to the development of new treatments.

EXPRESSION OF MESSENGER RNAS FOR MEMBRANE-TYPE 1, 2, AND 3 MATRIX METALLOPROTEINASES IN HUMAN RENAL CELL CARCINOMAS

1999 ◽  
Vol 162 (3 Part 1) ◽  
pp. 905-909 ◽  
Author(s):  
YASUHIDE KITAGAWA ◽  
KAZUTO KUNIMI ◽  
TADAO UCHIBAYASHI ◽  
HIROSHI SATO ◽  
MIKIO NAMIKI
Keyword(s):  
Matrix Metalloproteinases ◽  
Renal Cell ◽  
Messenger Rnas ◽  
Renal Cell Carcinomas ◽  
Membrane Type

994: Patients with Renal Cell Carcinomas have Increased Subsequent Occurrence of other Primary malignant tumours. - A National Cohort Study

2005 ◽  
Vol 173 (4S) ◽  
pp. 269-269
Author(s):  
Christian Beisland ◽  
Olaug Talleraas ◽  
August M. Bakke ◽  
Jarle Norstein
Keyword(s):  
Cohort Study ◽  
Renal Cell ◽  
Malignant Tumours ◽  
Renal Cell Carcinomas ◽  
National Cohort
Sign in / Sign up

Export Citation Format

Share Document